Quantcast

Latest Trastuzumab Stories

2011-07-25 05:36:00

Better Targeting of Pharmaceuticals to Patient's Genetic Profile Could Save $30B - $110B Annually WASHINGTON, July 25, 2011 /PRNewswire-USNewswire/ -- Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease. This according to Alan Mertz, president of the American Clinical Laboratory Association (ACLA): "Genetic testing is going to be a...

2011-07-18 16:05:57

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown. ABT-737 is one of a new class of anti-cancer agents called BH3 mimetics that target and neutralise the so-called Bcl-2 proteins in cancer cells. Bcl-2 proteins act to 'protect' the cells after they have been damaged by chemotherapy drugs, and prevent the cancer cells from dying....

2011-07-18 14:12:45

The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed. Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now know that these women should get trastuzumab and potentially chemotherapy, even if cancer spreads to the brain." "Women with HER2-positive breast cancer have a reasonable chance of living a long time...

2011-07-18 07:05:05

(Ivanhoe Newswire) -- There may be new hope for patients with advanced breast cancer. Researchers have found the use of trastuzumab, chemotherapy and surgery significantly improves survival and the time central nervous system metastases is diagnosed among patients with HER2-positive metastatic breast cancer. About 10 to 16 percent of women with advanced breast cancer develop central nervous system metastases, which means the cancer spreads to the brain. In this study, 377 of the 1,023 women...

2011-07-15 17:17:00

SAN DIEGO, July 15, 2011 /PRNewswire/ -- Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr. Kachioff will be responsible for management of the company's accounting, finance, treasury, investor relations, risk management and information systems functions. Kachioff has more than 20 years of leadership experience in helping to build life science companies. Prior to joining Biocept, Kachioff was...

2011-07-12 10:00:00

Part of agency's efforts to promote development of personalized medicines and diagnostics SILVER SPRING, Md., July 12, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today issued a new draft guidance to facilitate the development and review of companion diagnostics - tests used to help health care professionals determine whether a patient with a particular disease or condition should receive a particular drug therapy or how much of the drug to give. The draft...

2011-07-11 19:51:22

Combination therapy benefits more than a third of women in study Adding Afinitor® to Herceptin®, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology. The Phase I/II study demonstrated that a combination of the...

2011-06-28 13:13:52

Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)." In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D., and colleagues describe the molecular features of these six distinct subtypes and identify chemotherapies to which the different subtypes respond in cultured cells and animal tumor models. Knowing the...

2011-06-14 17:56:00

TUCSON, Ariz., June 14, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that the FDA approved the INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) for commercialization in the United States. This is the first fully automated assay approved by the FDA for determination of HER2 gene status in breast cancer as an aid in the assessment of patients considered for treatment with Herceptin (trastuzumab). For breast cancer...

2011-06-14 11:15:00

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related